When patients are forced to forego their medications due to high costs, the consequences are severe—not just for individual health outcomes, but also for public health and healthcare system costs. Policies that limit access to copay assistance exacerbate these challenges, disproportionately affecting those who are already vulnerable. House Bill 1216 represents an essential safeguard against harmful insurer practices, ensuring equitable access to life-saving treatments for North Dakota residents.
Support for NJ A-5217 to Ban Copay Accumulators
The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports Assembly Bill 5217. This vital legislation ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.
Support for Missouri Senate bill 45 to ensure all copays count for patients
The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports Senate Bill 45. This vital legislation ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.
Comments on Colorado’s draft PrEP guidance
We commend the Colorado Division of Insurance for taking the initiative to update state guidance on PrEP coverage. We support a finalized regulation and bulletin that clarifies that all PrEP medications and services must be covered without prior authorization or cost-sharing. We urge you to clarify that all FDA-approved PrEP medications must be covered without prior authorization or cost-sharing.
Letter on the nomination of Robert F. Kennedy, Jr. for Secretary of the Dept. of Health and Human Services
As the Committee considers the nomination of Robert F. Kennedy, Jr. to serve as Secretary of the Department of Health and Human Services, the HIV+Hepatitis Policy Institute, a leading national HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk for HIV, hepatitis, and other serious and chronic health conditions, urges you to ensure the nominee will uphold a commitment to science, the public health, and to ending HIV through robust research, treatment, and prevention programs.